4th Laupheim Biotech Days


In this conference with the title "Fusion Proteins - delivering novel therapeutic options"  we are examining the state of the art in developing fusion proteins as biopharmaceuticals, shedding light on the immense potential of design and functionality.


June 13 to 14, 2016


Schloss Großlaupheim, 88471 Laupheim, Germany

For more information download our Abstract book:

Abstract book 4th Laupheim Biotech Days


14:00 Tour of Rentschler’s facility
Rentschler Biotechnologie GmbH Laupheim, Germany
17:00 Reception & exhibition
Kulturhaus Schloss Großlaupheim Laupheim, Germany
18:00 Welcome
Rentschler Biotechnologie GmbH Laupheim, Germany

Genetic Engineering in Cell Culture Engineering:
A forward-looking review

Hansjörg Hauser
19:30 Dinner at the historical castle
Kulturhaus Schloss Großlaupheim Laupheim, Germany
09:00 Welcome
Stefan Schmidt
09:10 Therapeutic fusion proteins: Current trends and challenges
Stefan Schmidt
Half-life extension
09:30 PASylation: design of biologics with extended plasma half-life by genetic fusion with structurally disordered Pro/Ala-rich sequences as an alternative to chemical PEGylation
Arne Skerra
10:00 Recombinant albumin fusion proteins and half-life extension
Hubert Metzner
10:30 Coffee break
Toxic constructs
11:00 Hexavalent fusion proteins for cancer treatment and immune modulation: TRAIL, CD40L and beyond
Oliver Hill
11:30 TNF superfamily (TNFSF) ligand fusion proteins with enhanced receptor stimulatory activity
Harald Wajant
12:00 Antibody-ribonuclease fusion proteins (ImmunoRNases) for cancer therapy
Michaela Arndt
12:30 Lunch break and exhibition
Antibody derived molecules
13:30 Armed antibodies (from the bench to the clinic), with a special focus on antibody-cytokine fusion proteins
Dario Neri
14:00 Fynomabs
Wibke Lembke
14:30 Boosting natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies and bispecific immunoligands
Matthias Peipp
15:00 Coffee break
Bispecific scaffolds
15:30 Development of TandAbs for hematological and solid Tumors
 Erich Rajkovic
16:00 Nonclinical assessment of bispecific T-cell engaging antibody constructs (BiTE ®) and their transition into the clinic
Benno Rattel
16:30 Old target - new mode of action: how to create truly potent anti-ErbB2 agents
Martin Schwill
17:00 Final remarks and farewell “Get-Together”

Beverage Sponsor

Gold Sponsors

Silver Sponsors


Charles River